olomorasib + pemetrexed + carboplatin

**olomorasib + pemetrexed + carboplatin** is an investigational combination therapy consisting of olomorasib (a small molecule inhibitor of KRAS G12C), pemetrexed (an antifolate antineoplastic agent), and carboplatin (a platinum-based chemotherapy). Olomorasib selectively and covalently binds to the KRAS G12C mutant protein, inhibiting oncogenic signaling in tumors harboring this mutation[2][5]. Pemetrexed inhibits several enzymes involved in folate metabolism and DNA synthesis, while carboplatin induces DNA crosslinking, leading to apoptosis in rapidly dividing cells[3][6]. This combination is being studied primarily for the treatment of advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutations, aiming to improve antitumor activity in first-line and maintenance settings[2][5].